Navigation Links
Next Generation Trevo® System Launched in Europe - Trevo® Pro
Date:9/6/2011

MOUNTAIN VIEW, Calif., Sept. 6, 2011 /PRNewswire/ -- Concentric Medical, Inc. today announced the full European launch of Trevo® Pro 4 System. This next standard in Stentriever™ technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke.

The Trevo® Pro 4 system is the next generation of Trevo Stentrievers from Concentric Medical and is used to remove thrombus in stroke patients. It has a unique wide-cell geometry allowing the clot to more easily incorporate in the device. This unique cell and strut architecture, coupled with its proven radial force profile, are designed to further enhance clot retrieval in all clot types with fewer passes of the device in the procedure.

The Trevo Pro 4 device was introduced to a limited number of leading stroke centers in the spring. Fifty cases were completed in an initial evaluation post CE mark with very positive feedback from clinicians in Europe.

"The Trevo® Pro 4 System is a significant advance in the field of mechanical thrombectomy. I have had the opportunity to utilize this device in many procedures and have found the clot integration astonishing, regardless of the complexity of the clot. On many occasions I have achieved revascularization with one pass of the device," said Professor Olav Jansen, Head of Neuroradiology at Universitatsklinikum Schleswig-Holstein, Kiel, Germany.

Maria Sainz, President and CEO of Concentric Medical, also commented: "The Trevo Pro System has improved the predictability of the interventional stroke procedure for physicians. The device redefines the standard for success for physicians and patients. Concentric Medical is very proud to be able to offer the latest advancement in Trevo technology along with a full array of complementary tools for the entire stroke interventional procedure."

About Concentric Medical

Concentric Medical is located in Mountain View, California and is a global leader in the development of endovascular devices for revascularizing stroke patients. Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies.

For more information about Concentric Medical, please visit www.concentric-medical.com.

About the Trevo System

The Trevo System is an innovative, high-performing, easy-to-use thrombus retrieval system. The main component of the Trevo System is the Trevo Retriever which introduces Stentriever™ technology, creating a new generation of retrieval devices to remove clots in acute stroke patients.  Concentric Medical is the pioneer in developing devices for ischemic stroke intervention. Since 2002, Concentric Medical's devices have been used in thousands of stroke patients worldwide. This experience has been incorporated into the design of the Trevo System to make thrombus removal an easier, faster and more predictable procedure.   The new Trevo System combined with the Merci®Retriever, DAC® (Distal Access Catheters) and Balloon Guide Catheter portfolio of products, further strengthens Concentric Medical's position as a global leader in acute ischemic stroke intervention.  

About Acute Ischemic Stroke

Stroke is one of the leading causes of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain.

Media Contact:
+1 650-938-2100
strokeinfo@concentric-medical.com


'/>"/>
SOURCE Concentric Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
3. Beaumont Patients 1st to get Next Generation of Radiation Treatment
4. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
5. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
6. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/8/2017)... , June 8, 2017  StatLab Medical ... developer and manufacturer of diagnostic supplies for ... that Cressey & Company LP ("Cressey & ... completed a growth-focused investment in the Company. ... ownership position from selling shareholder, Prairie Capital, ...
Breaking Medicine Technology:
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... Zurich, Switzerland (PRWEB) , ... June 27, 2017 , ... ... crowd to manage token assets on the Ethereum blockchain, has released their technical ... but until now, there has been little systematic approach for determining which offerings will ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... to an upcoming case studies guidebook. This guidebook offers an excellent branding and ... will include articles, case studies and how-to’s that fall into the following categories:, ...
Breaking Medicine News(10 mins):